Scholarlink

<p>The current study focuses on the development of hollow mesoporous silica nanoparticles (HMSN) as nanocarriers for the effective delivery of 6-mercaptopurine (6MP) in breast cancer cells. FTIR spectroscopy confirmed structural integrity and drug encapsulation, displaying characteristic N–H, C-H, C-N, and S–H vibrations along with the Si–O-Si framework. EDX analysis revealed the presence of Si and O in unloaded HMSN, while additional C, N, and S peaks confirmed successful 6MP loading. TEM imaging demonstrated hollow cores and drug dispersion over HMSN structures, consistent with SEM observations of spherical morphology and an increase in particle size from 132 to 150&#xa0;nm after 6MP loading. BET analysis showed a substantial reduction in surface area and pore volume following encapsulation, exhibiting efficient pore filling. The drug loading efficiency was 79.54% after 48&#xa0;h, with pH-responsive release favouring acidic conditions (86.87% at pH 5.0) compared with physiological pH (68.69% at pH 7.4) condition. Release kinetics followed the Korsmeyer–Peppas super case-II mechanism, consistent with sustained release. Cytotoxicity studies against MCF-7 cells revealed strong anticancer activity (IC<sub>50</sub> = 37.4&#xa0;μg/mL), and apoptotic cell death confirmed through Ao/EtBr staining. Collectively, these findings highlight 6MP-loaded HMSN as a promising nanotherapeutic system for effective breast cancer treatment.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

pH-Responsive Delivery of 6-Mercaptopurine-Loaded Hollow Mesoporous Silica Nanoparticles for Breast Cancer Therapy

  • 期刊论文

  • 发表日期：

    2025年10月24日

查看全文
  • Anbarasu Krishnan,
  • Mary Anjalin Francis

摘要

The current study focuses on the development of hollow mesoporous silica nanoparticles (HMSN) as nanocarriers for the effective delivery of 6-mercaptopurine (6MP) in breast cancer cells. FTIR spectroscopy confirmed structural integrity and drug encapsulation, displaying characteristic N–H, C-H, C-N, and S–H vibrations along with the Si–O-Si framework. EDX analysis revealed the presence of Si and O in unloaded HMSN, while additional C, N, and S peaks confirmed successful 6MP loading. TEM imaging demonstrated hollow cores and drug dispersion over HMSN structures, consistent with SEM observations of spherical morphology and an increase in particle size from 132 to 150 nm after 6MP loading. BET analysis showed a substantial reduction in surface area and pore volume following encapsulation, exhibiting efficient pore filling. The drug loading efficiency was 79.54% after 48 h, with pH-responsive release favouring acidic conditions (86.87% at pH 5.0) compared with physiological pH (68.69% at pH 7.4) condition. Release kinetics followed the Korsmeyer–Peppas super case-II mechanism, consistent with sustained release. Cytotoxicity studies against MCF-7 cells revealed strong anticancer activity (IC50 = 37.4 μg/mL), and apoptotic cell death confirmed through Ao/EtBr staining. Collectively, these findings highlight 6MP-loaded HMSN as a promising nanotherapeutic system for effective breast cancer treatment.